Thursday, September 22, 2016 4:53:21 PM
Lantheus to Present New Data at the ASNC Annual Scientific Session on the Novel PET Cardiac Imaging Agent Flurpiridaz F 18 in Patients with Suspected Heart Disease Undergoing Exercise Stress Testing
Published: Sept 22, 2016 4:19 p.m. ET
Findings Show Superiority of Flurpiridaz F 18 PET MPI Compared to SPECT MPI for the Assessment of Coronary Artery Disease During Exercise Stress Testing
NORTH BILLERICA, Mass., Sep 22, 2016 (BUSINESS WIRE) -- Lantheus Holdings, Inc. LNTH, +4.86% the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents, today announced that new data from a sub-analysis of its first Phase 3 study of flurpiridaz F 18 for myocardial perfusion imaging (MPI) in patients undergoing exercise stress testing will be presented at the 21st Annual Scientific Session of the American Society of Nuclear Cardiology (ASNC) in Boca Raton, Florida. The findings show the superiority of flurpiridaz F 18, an investigational positron emission tomography (PET) agent for MPI, compared to MPI with single photon emission computed tomography (SPECT) for the assessment of coronary artery disease (CAD) during exercise stress testing.
The oral presentation entitled, “Exercise Stress Testing with Flurpiridaz F 18 PET and Tc99m SPECT Myocardial Perfusion Imaging for the Assessment of CAD: A Subset Analysis of the Flurpiridaz F 18 301 Phase 3 Study,” will be presented by Rob Beanlands, M.D. of University of Ottawa Heart Institute on Saturday, September 24, 2016 at 10:45 a.m. ET in the Featured Oral Abstracts session of the meeting.
“Due to short half-life limitations of currently available tracers ( [13] NH3 and [82] Rb), PET myocardial perfusion imaging is commonly used in conjunction with pharmacologic stress testing,” said Dr. Beanlands, the lead author of the presentation. “The ability to perform PET imaging with exercise stress would allow us to gather important additional clinical information and also to use the same camera for both stress modalities. The results of this study provide evidence of the particular utility and future potential of flurpiridaz F 18 PET imaging for the diagnosis of coronary artery disease.”
Based on a blinded read of PET and SPECT data, flurpiridaz F 18 PET imaging demonstrated a statistically greater sensitivity (67.0%) versus SPECT (54.9%) (p<0.016) but lower specificity (73.8%) versus SPECT (85.4%) (non-significant for non-inferiority testing). Improved diagnostic performance of flurpiridaz F 18 PET imaging versus SPECT was also observed by ROC analysis (p<0.05). A significantly higher percentage of images were rated as either excellent or good quality with flurpiridaz F 18 PET imaging, compared to SPECT for rest images (p<0.001). No drug-related serious adverse events were observed.
The data are from a multicenter, international (United States, Canada, and Finland) Phase 3 study of flurpiridaz F 18 PET imaging. The study enrolled approximately 800 patients with known or suspected CAD who were scheduled for coronary angiography and conventional SPECT. Of these patients, 221 patients with known or suspected CAD underwent exercise stress flurpiridaz F 18 PET and SPECT imaging and coronary angiography.
"The Phase 3 data sub-analysis presented at ASNC demonstrates the ability to conduct flurpiridaz F 18 PET imaging for coronary artery disease detection in association with exercise stress testing,” said Cesare Orlandi, M.D., Chief Medical Officer of Lantheus Medical Imaging. “Flurpiridaz F 18 PET imaging also shows superiority over SPECT in this subpopulation not assessable with current standard PET imaging modalities. We believe improved diagnostic accuracy, coupled with reduced radiation exposure and potential for quantification of coronary flow reserve provide great promise for flurpiridaz F 18 to become the diagnostic imaging agent of choice for evaluating coronary artery disease.”
Lantheus is poised to commence the second of two Phase 3 trials for flurpiridaz F 18 PET imaging with a revised protocol in place under an FDA-approved Special Protocol Assessment and is in active negotiations with potential strategic partners to assist with the further development, manufacture and commercialization of this promising agent.
Recent LNTH News
- Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024 • GlobeNewswire Inc. • 09/15/2024 12:45:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/13/2024 05:29:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2024 12:38:01 PM
- Lantheus Appoints Julie Eastland as New Board Member • GlobeNewswire Inc. • 09/05/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:30:03 PM
- Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference • GlobeNewswire Inc. • 08/28/2024 12:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/21/2024 08:35:06 PM
- Lantheus to Present Additional Clinical Data from Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024 • GlobeNewswire Inc. • 08/20/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 08:30:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 08:30:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:56:30 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/14/2024 04:41:30 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/13/2024 02:59:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 09:09:32 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 09:04:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 08:23:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/08/2024 03:16:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/06/2024 08:30:04 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/02/2024 08:21:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:50:41 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:47:34 AM
- Lantheus Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:32:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:30:34 PM
- Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time • GlobeNewswire Inc. • 07/17/2024 12:30:00 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM